Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 27 04:00PM ET
329.50
Dollar change
-0.41
Percentage change
-0.12
%
Index- P/E44.60 EPS (ttm)7.39 Insider Own0.88% Shs Outstand82.50M Perf Week-1.86%
Market Cap27.18B Forward P/E19.19 EPS next Y17.17 Insider Trans0.00% Shs Float81.77M Perf Month2.18%
Income612.34M PEG3.13 EPS next Q3.43 Inst Own99.44% Short Float1.83% Perf Quarter16.00%
Sales8.12B P/S3.35 EPS this Y16.88% Inst Trans0.86% Short Ratio2.66 Perf Half Y33.56%
Book/sh112.02 P/B2.94 EPS next Y14.89% ROA3.58% Short Interest1.49M Perf Year58.50%
Cash/sh4.61 P/C71.52 EPS next 5Y14.23% ROE6.90% 52W Range181.92 - 344.77 Perf YTD16.40%
Dividend Est.- P/FCF26.78 EPS past 5Y4.42% ROI4.70% 52W High-4.43% Beta1.15
Dividend TTM- Quick Ratio1.21 Sales past 5Y29.97% Gross Margin22.34% 52W Low81.12% ATR (14)7.72
Dividend Ex-Date- Current Ratio1.21 EPS Y/Y TTM20.27% Oper. Margin12.88% RSI (14)58.94 Volatility1.60% 2.32%
Employees41100 Debt/Eq0.43 Sales Y/Y TTM4.89% Profit Margin7.54% Recom1.53 Target Price351.79
Option/ShortYes / Yes LT Debt/Eq0.41 EPS Q/Q82.81% Payout0.00% Rel Volume0.96 Prev Close329.91
Sales Surprise-1.16% EPS Surprise0.02% Sales Q/Q5.31% EarningsFeb 21 AMC Avg Volume561.24K Price329.50
SMA20-0.92% SMA5010.45% SMA20024.39% Trades Volume541,108 Change-0.12%
Date Action Analyst Rating Change Price Target Change
Dec-15-23Initiated Truist Buy $357
Sep-13-23Initiated TD Cowen Outperform $306
Jan-17-23Upgrade Barclays Equal Weight → Overweight $215 → $260
Jan-13-23Upgrade Barclays Equal Weight → Overweight
Nov-09-22Upgrade BofA Securities Neutral → Buy $265 → $260
Sep-07-22Initiated UBS Buy $270
Aug-25-22Initiated Credit Suisse Neutral $260
May-24-22Initiated Guggenheim Buy $285
Apr-25-22Downgrade Wells Fargo Overweight → Equal Weight $250
Apr-12-22Upgrade Deutsche Bank Hold → Buy $234 → $310
Mar-25-24 04:15PM
Mar-22-24 11:30AM
Mar-15-24 08:50AM
Mar-04-24 11:26AM
Feb-29-24 12:00PM
12:00PM Loading…
Feb-28-24 12:00PM
08:50AM
Feb-26-24 04:15PM
12:25PM
Feb-23-24 09:00AM
Feb-22-24 04:35PM
Feb-21-24 06:30PM
04:15PM
Feb-09-24 10:18PM
Jan-30-24 06:00AM
07:00AM Loading…
Jan-24-24 07:00AM
Jan-10-24 06:30PM
Jan-09-24 08:00AM
Jan-08-24 07:00AM
Jan-04-24 07:00AM
Dec-18-23 07:15AM
Dec-11-23 06:41PM
Dec-08-23 06:00AM
Dec-07-23 04:15PM
Nov-20-23 12:45PM
Nov-13-23 09:02PM
Nov-08-23 06:00AM
Nov-06-23 12:27PM
Nov-01-23 12:45PM
Oct-30-23 01:06PM
03:29PM Loading…
Oct-27-23 03:29PM
Oct-26-23 03:29PM
Oct-25-23 06:30PM
04:15PM
Oct-23-23 10:00AM
Oct-12-23 09:07AM
Oct-02-23 08:17PM
Sep-28-23 05:00PM
Sep-21-23 11:40AM
06:00AM
Sep-20-23 07:15AM
Sep-18-23 06:20AM
Sep-13-23 07:31AM
07:15AM
Sep-06-23 06:00AM
Sep-05-23 11:40AM
Aug-18-23 11:40AM
Aug-17-23 08:39AM
Jul-29-23 08:03AM
Jul-28-23 02:19PM
Jul-26-23 06:55PM
04:20PM
04:15PM
Jul-20-23 11:40AM
Jul-19-23 10:01AM
Jul-13-23 07:15AM
Jul-03-23 09:54AM
Jun-27-23 04:15PM
Jun-26-23 07:15AM
06:00AM
Jun-02-23 06:41PM
May-31-23 06:00AM
May-27-23 10:16AM
May-16-23 06:00AM
May-08-23 11:08AM
Apr-27-23 09:28PM
Apr-26-23 06:55PM
04:32PM
Apr-25-23 06:45PM
Mar-29-23 02:05PM
06:00AM
Mar-25-23 07:20AM
Mar-13-23 07:46AM
Mar-10-23 02:00AM
Feb-27-23 04:15PM
12:46PM
Feb-24-23 05:10AM
Feb-22-23 08:05PM
04:30PM
Feb-13-23 11:58PM
Feb-07-23 12:10PM
Feb-06-23 05:14PM
Jan-26-23 04:15PM
Jan-23-23 08:02AM
Jan-11-23 10:10AM
Jan-10-23 06:24PM
08:45AM
Jan-03-23 04:15PM
Dec-26-22 10:25PM
Dec-13-22 07:00AM
Dec-12-22 09:15AM
Nov-29-22 10:02AM
Nov-23-22 04:15PM
Nov-02-22 07:45PM
04:15PM
01:31PM
Oct-26-22 10:01AM
Oct-24-22 09:37AM
Oct-18-22 03:23PM
Oct-17-22 02:07PM
ICON plc operates as a clinical research organization, which engages in the provision of outsourced development services to the pharmaceutical, biotechnology, and medical device industries. It specializes in the development, management and analysis of programs that support clinical development. It operates through the following geographical segments: Ireland, Rest of Europe, U.S. and Other. The company was founded by John Climax and Ronan Lambe in June 1990 and is headquartered in Dublin, Ireland.